The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 were made on 8 June 2026 and will come into force on 29 June 2026. Signed by Home Office minister Sarah Jones, the instrument uses powers in the Retained EU Law (Revocation and Reform) Act 2023 and was approved by both Houses of Parliament. Drug precursors are lawful chemicals with legitimate industrial and medical uses, but they can also be diverted into the manufacture of illicit drugs. The new regulations are mainly a legal and administrative rewrite rather than a fresh policy line on criminal enforcement. Most of the instrument extends across the UK, but Regulations 5 to 8 apply only in England and Wales and Scotland, while Regulation 9 and the Schedule apply only to Northern Ireland.
The reason Northern Ireland is treated differently is set out clearly in the Explanatory Note. Article 5(4) of the Windsor Framework provides that certain EU law listed in Annex 2 continues to apply in and to the UK in respect of Northern Ireland. That includes Regulation (EC) No 273/2004 on drug precursors and Council Regulation (EC) No 111/2005 on trade between the Union and third countries in drug precursors. Great Britain now operates through domestic secondary assimilated law based on those former EU rules, while Northern Ireland remains subject to the live EU versions. That is why the instrument repeatedly replaces references to "the United Kingdom" with "Great Britain" and then makes separate provision for Northern Ireland. For policy teams and regulated operators, that is the main legal point: one regime is now being expressed through two territorial routes.
Regulations 2 and 3 amend the 2008 instruments covering intra-Community trade and external trade in drug precursors. In practice, those amendments rewrite the interpretation sections so that the same regulation titles can refer to one version of the law in Northern Ireland, where EU law still applies, and another version in Great Britain, where the texts survive as assimilated domestic law. The amendments also identify who may act as a competent authority in Northern Ireland for certain purposes. The list includes constables, HMRC officers or others authorised by HMRC, persons authorised by the Director General of the National Crime Agency, and the Secretary of State. The offence and penalty provisions are also clarified so that "scheduled substances" are read by reference to the relevant precursor regulations themselves, reducing doubt over whether older domestic wording still matches the current control lists.
For external trade, the Northern Ireland provisions go beyond drafting clean-up. The regulations insert express duties for operators dealing with scheduled substances where customs declarations are required. For exports from Northern Ireland, operators must hold a valid export authorisation and present it to the customs office when the declaration is made, or at the point of exit where no declaration is required. For Category 1 substances imported into the customs territory of the Union through Northern Ireland, operators must obtain and present a valid import authorisation. The practical result is that movements involving Northern Ireland are tied more directly to EU customs territory procedures where the law requires it. Businesses that had read the older 2008 texts as mainly UK-wide enforcement rules will now need to read them alongside customs process, licensing arrangements and the location of the transaction.
Regulation 4 makes a narrower but commercially relevant change to the 2010 fee regulations. It updates the charging provisions so they refer to the new authorisation routes inserted elsewhere in the instrument, but it also creates a specific fee exemption for export and import authorisations issued for movements of scheduled substances between Great Britain and Northern Ireland. That does not remove the need for authorisations where the regime requires them. It does, however, remove a direct administrative charge that might otherwise have attached to these internal UK movements. For chemical suppliers, wholesalers, healthcare distributors and freight agents, the position is therefore mixed: the paperwork remains, but one possible cost has been disapplied.
Regulations 5 to 8 amend the Great Britain versions of the 2004 and 2005 precursor regulations, together with later delegated and implementing measures. Much of that work is textual. References to the United Kingdom are narrowed to Great Britain, definitions such as "natural product" are updated, the Secretary of State is written into licensing procedures where the old EU text referred to member states, and obsolete form material is removed from the Great Britain regime. The Explanatory Note also points to a substantive change. The annexes to Regulation (EC) No 273/2004 and Council Regulation (EC) No 111/2005 are amended so that the drug precursor chemicals controlled in Great Britain are brought into line with those already controlled in Northern Ireland under EU law. That reduces the chance of different substance lists applying across the UK, even though the legal basis remains different on each side of the Irish Sea.
Regulation 9 revokes the listed domestic instruments so far as they extend to Northern Ireland. The logic is straightforward. Where the same subject matter continues to be governed in Northern Ireland through EU law under the Windsor Framework, parallel domestic instruments risk duplication and conflicting interpretation. The revocation is therefore part of the same statute book repair exercise as the rest of the regulations. The government states that no full impact assessment has been produced because no, or no significant, effect on the private, voluntary or public sector is foreseen. Even so, the compliance effect is clear. From 29 June 2026, anyone dealing in regulated precursor chemicals will need to check not only the substance and the type of transaction, but also whether the movement concerns Great Britain, Northern Ireland or the wider EU customs territory. For legal advisers, policy officials and regulated businesses, the instrument is a precise example of how retained EU law reform is being translated into operational rules.